🇺🇸

US SEC Filing Intelligence

· daily

New Federal Contractors — March 29, 2026

Five new federal contracts totaling $1.33B in obligations signal bullish momentum for health/tech and security providers, with HHS dominating at ~$699M (53% of total) via CMS software verification and NIH R&D. Long-term performance periods to 2027-2029 offer revenue stability, though options could unlock $6B+ upside across portfolios. Neutral stance on nonprofit Family Endeavors due to T&M pricing and shorter horizon, but overall portfolio supports overweight in gov-contracted health R&D and IT services.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 29, 2026

Five significant contract modifications totaling $1.33B in obligations highlight sustained federal demand in health services (52% HHS allocation via Carahsoft and Leidos), with four bullish signals driven by long-term commitments to 2027-2029 and massive option upside exceeding $5B combined. Neutral signal on nonprofit Family Endeavors reflects full $347M outlay but limited scalability. Investors should prioritize Leidos, Carahsoft for revenue visibility amid firm fixed price risks and low outlays in select contracts like Idemia.

5 total filings
· daily

Contract Deobligations Alert — March 29, 2026

Five contract deobligations totaling $1.33B highlight sustained U.S. government commitments to health/tech services (52% of value via HHS), facilities support, security, and investment management, with 4 bullish signals driven by high outlays ($1.1B already spent across records) and long-term horizons to 2029. Largest exposures favor Carahsoft ($465M HHS software) and Family Endeavors ($347M DOI facilities), signaling portfolio stability for institutional holders in defense/health contractors. Neutral Family Endeavors stands out as nonprofit with massive unexercised options ($3.3B potential), warranting scrutiny amid bullish peers.

5 total filings
· daily

Contract Option Exercises — March 29, 2026

Option exercises totaling $1.33B signal strong long-term U.S. government commitments through 2029, dominated by HHS ($699M across two contracts) in software publishing and biomed R&D, yielding 4 bullish signals for Leidos Holdings, Carahsoft, IDEMIA, and NISA. Neutral stance on nonprofit Family Endeavors due to T&M pricing and short horizon despite $3.3B options upside. Investors should prioritize public Leidos for predictable revenue, monitor $0 outlays on IDEMIA's $204M, and track HHS expansion risks/opportunities.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — March 29, 2026

Carahsoft Technology Corp secured a $465M obligated delivery order from CMS (HHS) for income verification software, with $337M already outlayed and potential upside to $2.1B via options through 2028. This represents a major bullish signal for federal IT/software publishers amid healthcare admin digitization. Investors should monitor option exercises and outlays for revenue acceleration, tempered by firm-fixed-price margin risks.

1 total filings
· daily

All HHS Contracts — March 29, 2026

HHS data reveals $698.6M in major contracts to Carahsoft ($465M obligation, $2.07B potential) for CMS income verification software and Leidos ($233.6M fully obligated) for NIH COVID-19 R&D, both bullish with $493.5M (71%) already outlayed for multi-year revenue through 2029. These awards underscore sustained HHS demand for digital verification tools and biomed R&D amid full/open competition. Investors gain clear long-term visibility, prioritizing Carahsoft's massive option upside.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 29, 2026

Four mega contracts totaling $1.25B in obligations highlight sustained federal spending in HHS (56% of value) for software verification and biomedical R&D, plus facilities support and passport services, with 3 bullish signals for corporate recipients. Massive optionality exceeds $5.6B combined (Carahsoft $2.1B, Family Endeavors $3.3B), offering multi-year upside through 2029, though $0 outlays on IDEMIA's 2017 award flags execution delays. Investors should prioritize Leidos and Carahsoft for stable health/tech revenues amid long-duration commitments.

4 total filings
· daily

High-Value Federal Grants ($5M+) — March 29, 2026

Five high-value federal contracts total $1.33B obligated (potential $8.8B with options), dominated by HHS awards (52% of value) signaling robust health/services demand. Four bullish signals highlight long-term revenue for Leidos Holdings, Carahsoft, IDEMIA, and NISA, with 47% average outlay progress and extensions to 2029. Neutral Family Endeavors stands out as nonprofit with 10x option upside amid facilities support needs.

5 total filings
· daily

General Federal Contracts — March 29, 2026

Federal contracts totaling $1.33B obligated, with 4/5 bullish signals dominated by HHS ($698.6M across software verification and COVID R&D), signaling robust health sector commitments through 2028-2029. Long-term performance periods (avg. ~4-10 years remaining) and partial outlays ($865M total) indicate steady revenue visibility for winners like Carahsoft and Leidos. Neutral signal on nonprofit Family Endeavors highlights facilities support scale-up potential amid options exceeding $3.3B.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 28, 2026

A single significant $108M contract modification awarded to CGI Federal Inc. (Timken subsidiary) for EPA IT enterprise development signals strong federal demand in IT services, with potential expansion to $523M via options through 2030. This bullish development underscores GSA's reliance on cost-plus structures for environmental agency tech support. Investors should monitor option exercises amid execution risks from subawards and performance fees.

1 total filings
· daily

Contract Deobligations Alert — March 28, 2026

CGI Federal Inc., listed as a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT support, with potential expansion to $523M through options extending to 2030. No outlays yet signal early-stage execution, presenting bullish upside if options are exercised amid zero deobligations in this period. Investors should monitor performance evaluations and subaward costs for margin risks in govcon IT.

1 total filings
· daily

Contract Option Exercises — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M via options through 2030. This bullish signal provides multi-year revenue visibility in government IT services, though realization hinges on performance-based options and award fees. No outlays yet signal early-stage execution, warranting monitoring for margin impacts from $15M subawards.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 28, 2026

CGI Federal Inc. secured a $108M obligated GSA delivery order for EPA IT enterprise development, with potential expansion to $522M through options by 2030, signaling strong federal demand in IT services. No funds outlayed yet, but long performance window to 2030 offers upside if options exercised. Investors should monitor performance evaluations amid subaward commitments and cost-plus structure risks.

1 total filings
· daily

Biotech Small-Cap Approvals — March 27, 2026

Two small-cap biotech ANDA approvals on March 24, 2026, for Ascent Pharms (Guanfacine Hydrochloride) and Zhejiang Jingxin (Ticagrelor) signal neutral generic market entries with no special designations or specified indications. Lacking premium positioning or expedited review, these offer limited differentiation amid standard generic competition. Investors should note steady commoditization in biotech small-caps but no material portfolio catalysts.

2 total filings
· daily

New Drug Approvals (Original) — March 27, 2026

FDA approved two generic ANDA products on March 24, 2026: Guanfacine Hydrochloride (Ascent Pharms Inc) and Ticagrelor (Zhejiang Jingxin), both under standard review with no special designations or specified indications. Neutral investment signals prevail due to generic nature and lack of differentiation or market details. Pattern indicates routine generic pipeline progress without material sector disruption or premium opportunities.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 27, 2026

Three bullish federal contracts totaling $472M signal sustained U.S. government demand for construction in infrastructure resilience, embassy facilities, and disaster recovery across DOI, DOS, and DHS. Full base+options obligations provide revenue visibility to 2027 for Tutor Perini ($117M), Caddell ($168M), and BWI TPC JV ($187M near-complete), though firm-fixed-price terms and low aggregate outlays (~40%) flag execution risks. Cross-pattern: Full/open awards to non-small contractors highlight competitive strength in NAICS 236220/237990, with phased/hurricane work priming follow-ons.

3 total filings